BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 11950687)

  • 1. Factor V and thrombotic disease: description of a janus-faced protein.
    Nicolaes GA; Dahlbäck B
    Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):530-8. PubMed ID: 11950687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
    Pezeshkpoor B; Castoldi E; Mahler A; Hanel D; Müller J; Hamedani NS; Biswas A; Oldenburg J; Pavlova A
    J Thromb Haemost; 2016 Jul; 14(7):1353-63. PubMed ID: 27090446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of individual activated protein C cleavage site regions in coagulation factor V for factor Va inactivation and for factor Xa activation.
    Heeb MJ; Rehemtulla A; Moussalli M; Kojima Y; Kaufman RJ
    Eur J Biochem; 1999 Feb; 260(1):64-75. PubMed ID: 10091585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va.
    Cramer TJ; Griffin JH; Gale AJ
    Pathophysiol Haemost Thromb; 2010; 37(1):17-23. PubMed ID: 20501981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation.
    Tans G; Nicolaes GA; Rosing J
    Semin Hematol; 1997 Jul; 34(3):244-55. PubMed ID: 9241709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional properties of factor V and factor Va encoded by the R2-gene.
    Hoekema L; Castoldi E; Tans G; Girelli D; Gemmati D; Bernardi F; Rosing J
    Thromb Haemost; 2001 Jan; 85(1):75-81. PubMed ID: 11204592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of factor V by the anticoagulant protease activated protein C: Influence of the B-domain and TFPIα.
    Ayombil F; Petrillo T; Kim H; Camire RM
    J Biol Chem; 2022 Nov; 298(11):102558. PubMed ID: 36183835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
    Dahlbäck B
    Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated protein C, protein S, and tissue factor pathway inhibitor cooperate to inhibit thrombin activation.
    Li X; Song X; Mahmood DFD; Sim MMS; Bidarian SJ; Wood JP
    Thromb Res; 2023 Oct; 230():84-93. PubMed ID: 37660436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations.
    Castoldi E; Brugge JM; Nicolaes GA; Girelli D; Tans G; Rosing J
    Blood; 2004 Jun; 103(11):4173-9. PubMed ID: 14976057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V.
    Thorelli E; Kaufman RJ; Dahlbäck B
    J Biol Chem; 1998 Jun; 273(26):16140-5. PubMed ID: 9632668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor V Leiden: a disorder of factor V anticoagulant function.
    Castoldi E; Rosing J
    Curr Opin Hematol; 2004 May; 11(3):176-81. PubMed ID: 15257017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor V Leiden: association with venous thromboembolism in pregnancy and screening issues.
    Harvey D; Lowe GM
    Br J Biomed Sci; 2004; 61(3):157-64. PubMed ID: 15462267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene.
    Aparicio C; Dahlbäck B
    Biochem J; 1996 Jan; 313 ( Pt 2)(Pt 2):467-72. PubMed ID: 8573079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor Va-factor Xa interactions: molecular sites involved in enzyme:cofactor assembly.
    Steen M
    Scand J Clin Lab Invest Suppl; 2002; 237():5-11. PubMed ID: 12570161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden.
    Nogami K; Shinozawa K; Ogiwara K; Matsumoto T; Amano K; Fukutake K; Shima M
    Blood; 2014 Apr; 123(15):2420-8. PubMed ID: 24523236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms that regulate the anticoagulant function of coagulation factor V.
    Thorelli E
    Scand J Clin Lab Invest Suppl; 1999; 229():19-26. PubMed ID: 10097286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The roles of factor Va and protein S in formation of the activated protein C/protein S/factor Va inactivation complex.
    Gierula M; Salles-Crawley II; Santamaria S; Teraz-Orosz A; Crawley JTB; Lane DA; Ahnström J
    J Thromb Haemost; 2019 Dec; 17(12):2056-2068. PubMed ID: 31364267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein Z-dependent protease inhibitor (ZPI) is a physiologically significant inhibitor of prothrombinase function.
    Huang X; Swanson R; Kroh HK; Bock PE
    J Biol Chem; 2019 May; 294(19):7644-7657. PubMed ID: 30918026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders.
    Dahlbäck B
    Int J Lab Hematol; 2016 May; 38 Suppl 1():4-11. PubMed ID: 27161771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.